AKT1 and familial dilated cardiomyopathy: Myr treatment was found to enhance the phosphorylation of Akt and GSK-3β and to restrain the phosphorylation of ERK1/2, exerting its anti-oxidative and anti-inflammatory roles in the protection against DCM.